RCKT
Rocket Pharmaceuticals, Inc. Common Stock
Nasdaq · usd
Stock performance
How Rocket Pharmaceuticals, Inc. Common Stock (RCKT) stock has performed from one day to one year, with its 52-week range.
- 1D
- -2.05%
- 1W
- -2.25%
- 1M
- -9.32%
- YTD
- -32.05%
- 1Y
- -24.29%
- 52-wk range
- $2.17 – $5.45
Key statistics
Today's trading snapshot for RCKT: day range, open, previous close, volume and market cap.
- Day range
- —
- Open
- —
- Prev close
- $2.39
- Volume
- 0
- Market cap
- $261.81M
- Shares out
- 109.77M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Rocket Pharmaceuticals, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 0.71
- P/FCF
- —
- ROE
- -4.7%
- ROA
- -4.1%
- Debt/Equity
- 0.06
- Div yield
- 0.00%
As of Nov 6, 2026
8-K filings
Material corporate events Rocket Pharmaceuticals, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Investor presentationOct 6, 2026
Additionally, the Company prepared an investor presentation providing certain updates on the Company's Danon Disease Program used in a corporate webinar on October 6, 2026.
- Regulatory decisionSep 15, 2026
On September 15, 2026, Rocket Pharmaceuticals, Inc. issued a press release announcing alignment with the U.S. Food and Drug Administration on continued enrollment and dosing and key elements of the global pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease.
- Executive compensation changeAug 27, 2026
Pursuant to the Stevens Amendment, if Mr. Stevens' employment is terminated by the Company without Cause or by Mr. Stevens for Good Reason, he is entitled to receive, subject to his execution and non-revocation of a release of claims: (i) a lump sum payment equal to 12 months of his base salary; (ii) any incentive bonus to which he is otherwise entitled for the prior fiscal year; and (iii) a lump sum amount equal to 12 months of COBRA premiums.
- Clinical trial resultsAug 3, 2026
On August 3, 2026, Rocket Pharmaceuticals, Inc. (the "Company") issued a press release announcing a positive clinical safety update regarding the initial three patients treated under the modified protocol for its global, pivotal Phase 2 trial of RP-A501 in Danon disease.
- Executive officer departureJun 30, 2026
On June 24, 2026, John Militello informed Rocket Pharmaceuticals, Inc. (the "Company" or "Rocket") of his resignation as VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer, effective July 7, 2026, to pursue other opportunities.
RCKT short interest
How heavily RCKT is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 6.7
- Short interest
- 16.28M
- Avg volume
- 2.44M
As of · reported to FINRA twice monthly.
RCKT news
The latest news and headlines about Rocket Pharmaceuticals, Inc. Common Stock (RCKT).
- ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmnegativeGlobeNewswire Inc.· Oct 23, 2025
- DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsnegativeGlobeNewswire Inc.· Aug 11, 2025
- RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKTnegativeGlobeNewswire Inc.· Aug 10, 2025
- Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitnegativeBenzinga· Aug 8, 2025
- MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitnegativeGlobeNewswire Inc.· Aug 7, 2025
Frequently asked questions
What is the Rocket Pharmaceuticals, Inc. Common Stock (RCKT) stock price today?
Massive provides real-time and historical Rocket Pharmaceuticals, Inc. Common Stock (RCKT) quotes via REST API, WebSocket and MCP.
What is Rocket Pharmaceuticals, Inc. Common Stock?
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for…
What is the short interest in RCKT?
As of Oct 15, 2026, RCKT has 16.28M shares short and 6.7 days to cover.
What exchange is RCKT listed on?
Rocket Pharmaceuticals, Inc. Common Stock (RCKT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of RCKT with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a RCKT analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.